Find a Doctor

Marcus H. Maurer

Humboldt Universität Zu Berlin And Berlin Institute Of Health
Male

Bio


Marcus Maurer is in Berlin, Germany. They have been an author on 621 peer reviewed articles and participated in 3 clinical trials in the past 15 years.

Contact

Berlin, BE, DE

Latest Advances


Latest Advance
Study
  • Condition: Delayed Pressure Urticaria (DPU)
  • Journal: The journal of allergy and clinical immunology. In practice
  • Treatment Used: Antihistamines
  • Number of Patients: 0
  • Published —
This review of the literature examined treatments for delayed pressure urticaria (hives; DPU).
Latest Advance
Study
  • Condition: Chronic Spontaneous Urticaria
  • Journal: The New England journal of medicine
  • Treatment Used: Ligelizumab vs. Omalizumab
  • Number of Patients: 382
  • Published —
The purpose of this study was to compare the effectiveness of ligelizumab versus omalizumab in patients with chronic spontaneous urticaria.
Latest Advance
Study
  • Condition: Cold Urticaria (ColdU)
  • Journal: The Journal of allergy and clinical immunology
  • Treatment Used: Nonsedating Second-Generation H1-Antihistamines (nsAHs)
  • Number of Patients: 0
  • Published —
This review of the literature analyzed the effectiveness and safety of cold urticaria (itchy weals; ColdU) treatments.
Latest Advance
Study
  • Condition: Hereditary angioedema
  • Journal: JAMA
  • Treatment Used: Lanadelumab
  • Number of Patients: 125
  • Published —
This study assessed the efficacy of lanadelumab in preventing hereditary angioedema attacks.
Latest Advance
Study
  • Condition: Hereditary Angioedema in German Patients
  • Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
  • Treatment Used: Icatibant
  • Number of Patients: 685
  • Published —
This study compared demographic and icatibant treatment outcomes in patients with with hereditary angioedema with C1 inhibitor deficiency (a rare disease of subcutaneous and submucosal swelling; HAE-C1-INH) from Germany to HAE-C1-INH patients from 11 other Icatibant Outcome Survey countries.
Latest Advance
Study
  • Condition: Chronic Spontaneous Urticaria
  • Journal: Allergy
  • Treatment Used: Omalizumab
  • Number of Patients: 30
  • Published —
This study tested the safety and efficacy of using omalizumab to treat patients with chronic spontaneous urticaria.
Latest Advance
Study
  • Condition: Hereditary Angioedema
  • Journal: Allergy
  • Treatment Used: Avoralstat vs. Placebo
  • Number of Patients: 110
  • Published —
This study evaluated the effectiveness and safety of prophylactic avoralstat (inhibitor of plasma kallikrein) versus placebo to treat patients with hereditary angioedema (recurrent attacks of severe swelling).
Latest Advance
Study
  • Condition: Chronic spontaneous urticaria (CSU) with angioedema
  • Journal: Allergy
  • Treatment Used: Omalizumab
  • Number of Patients: 91
  • Published —
This study evaluated the clinical outcomes and quality of life (QoL) of using omalizumab in patients suffering from chronic spontaneous urticaria (CSU) with angioedema.

All Publications
View All


Publication
Study
  • Journal: Allergy
  • Published —
The global impact of the COVID-19 pandemic on the management and course of chronic urticaria.
Publication
Study
  • Journal: Allergy
  • Published —
Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study.

Contact

Berlin, BE, DE

Insurance

Contact them to find out if they accept your insurance plan.